Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C.

Osteoporos Int. 2013 Jan;24(1):209-17. doi: 10.1007/s00198-012-2068-9. Epub 2012 Jul 26.

2.

Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D.

Menopause. 2015 Sep;22(9):1021-5. doi: 10.1097/GME.0000000000000466.

PMID:
25944523
3.
4.
5.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

6.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
7.

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women.

Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L.

BMC Musculoskelet Disord. 2011 Sep 26;12:209. doi: 10.1186/1471-2474-12-209. Review.

8.

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R.

Pharmacoeconomics. 2011 Nov;29(11):951-61. doi: 10.2165/11589310-000000000-00000. Review.

PMID:
21854080
9.

Vitamin K to prevent fractures in older women: systematic review and economic evaluation.

Stevenson M, Lloyd-Jones M, Papaioannou D.

Health Technol Assess. 2009 Sep;13(45):iii-xi, 1-134. doi: 10.3310/hta13450. Review.

10.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP.

Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2. Review.

PMID:
24773456
11.

Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.

Iwamoto J, Sato Y, Takeda T, Matsumoto H.

Drugs Aging. 2012 Mar 1;29(3):191-203. doi: 10.2165/11597480-000000000-00000. Review. Retraction in: Drugs Aging. 2017 Apr 8;:. Drugs Aging. 2017 May;34(5):415.

PMID:
22372723
12.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
13.

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Kanis JA, Johansson H, Oden A, McCloskey EV.

Osteoporos Int. 2011 Aug;22(8):2347-55. doi: 10.1007/s00198-010-1474-0. Epub 2011 Feb 2. Erratum in: Osteoporos Int. 2011 Aug;22(8):2357-8.

PMID:
21287148
14.

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.

Osteoporos Int. 2009 Oct;20(10):1663-73. doi: 10.1007/s00198-008-0825-6. Epub 2009 Jan 20.

15.
16.

Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.

Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B.

Eur Rev Med Pharmacol Sci. 2013 Mar;17(5):658-67.

17.

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.

Osteoporos Int. 2012 Mar;23(3):1115-22. doi: 10.1007/s00198-011-1847-z. Epub 2011 Nov 29.

18.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005326. Review.

PMID:
17054253
19.

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.

Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.

Arthritis Rheum. 2008 Jun;58(6):1687-95. doi: 10.1002/art.23461.

20.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819

Supplemental Content

Support Center